Biomatter Secures $18M to Innovate AI-Powered Enzyme Design

Biomatter, a firm specializing in custom enzyme design, has raised $18 million in a Series A funding round. The round was led by Astanor, with contributions from UVC Partners, Inventure, and Metaplanet. The company aims to enhance its AI-driven enzyme design capabilities, targeting global industry leaders including AstraZeneca and Sanofi.

The funds will be used to expand Biomatter's commercial team and establish a new facility in Vilnius. This facility is intended to accelerate the enzyme design process, reducing it from weeks to days. Additionally, Biomatter plans to increase its presence in the US market, where it serves roughly half of its customer base.

Biomatter has already delivered over 50 custom enzymes and collaborates with major companies like Thermo Fisher Scientific to improve enzyme stability. The company’s unique approach involves designing enzymes based on required chemical reactions rather than modifying existing natural enzymes.